3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
11
Phase 3
8
Phase 1
6
Phase NA
2
Phase 4
2
Phase 1/2
2
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
17
Multiple Myeloma
11
Neoplasms
8
Vomiting
6
Nausea
5
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Pain, Postoperative
2
Neoplasm, Residual
2
Lymphoma
2
Carcinoma, Non-Small-Cell Lung
2
Burkitt Lymphoma
2
Breast Neoplasms
2
Wrist Fractures
1
Systemic Inflammatory Response Syndrome
1
Supratentorial Neoplasms
1
Radicular Cyst
1
Postoperative Nausea and Vomiting
1
Postoperative Complications
1
Peripheral Nervous System Diseases
1
Ovarian Neoplasms
1
Mediastinal Neoplasms
1
Malnutrition
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphohistiocytosis, Hemophagocytic
1
Interventions
Zoledronic Acid
14
Leuprolide
9
bicalutamide
6
Triptorelin Pamoate
6
Goserelin
6
luprolide acetate gel depot
5
enzalutamide
5
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
5
Dutasteride
5
fluciclovine F-18
3
darolutamide
3
Sodium Chloride
3
Prednisone
3
Magnetic Resonance Spectroscopy
3
Flutamide
3
Androgen Antagonists
3
Abiraterone Acetate
3
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
3
cabazitaxel
2
Propofol
2
Prednisolone
2
Lidocaine
2
Gonadotropin-Releasing Hormone
2
Finasteride
2
Dexamethasone
2
Desflurane
2
Ciprofloxacin
2
testosterone 17 beta-cypionate
1
semaglutide
1
polyethylene glycol 3350
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 4
×
Prostatic Neoplasms
×
Dexamethasone
×
Clear all
NCT03432949
2024-01-24
TRANCE
University Health Network, Toronto
Phase 4
Unknown
24 enrolled
NCT02441894
2017-01-24
PEGAZUS
Sanofi
Phase 4
Completed
21 enrolled